Edward Hu
Co-CEO @ WuXi AppTec
Shanghai, China
Edward Hu is a Series A investor at WuXi AppTec in Shanghai focused on Biotechnology and Therapeutics. Formerly Senior Vice President and Chief Operating Officer at Tanox, responsible for operations, finance, IT, project management and strategic planning. MBA and M.S. in Chemistry from Carnegie Mellon University.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 40%
Last updated:
For AI agents: llms.txt
Industries Edward Hu invests in
Stages Edward Hu invests in
Countries Edward Hu invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (60%)
- Therapeutics 2 (40%)
- Pharmaceutical 2 (40%)
- Medical 1 (20%)
- Life Science 1 (20%)
Stage
- Series A 2 (40%)
- Series B 2 (40%)
- Series C 1 (20%)
Country
- United States 3 (60%)
- China 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Guangzhou Baseline Medical is committed to building a world-class clinical application of high-throughput sequencing and R & D platform to become the leading global provider of precision medical solutions. The company's core team has more than 20 years of senior industry experience, involved in cancer genomics, genetics and bioinformaticsand other fields.Based on its core technical advantages, the Company aims at precision medicine, establishes a cooperative relationship with middle and downstream enterprises in the industry, and forms a complete industrial chain from academic research to clinical product transformation. It has also established close cooperation with many large-scale third-party inspection agencies including Illumina, Well-known domestic and foreign hospitals and research institutes to establish cooperative relations, the development of a series of independent intellectual property rights and international competitiveness of clinical testing products for patients, doctors and medical institutions to provide accurate, convenient and comprehensive services. | $40M / Series C / Feb 22, 2021 | ||
| Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. | $70M / Series A / Sep 18, 2017 | ||
| Vivace Therapeutics is a venture-backed start-up dedicated to discovering and developing cancer therapeutics by targeting a novel pathway. At Vivace Therapeutics, they pursue their work with passion, driven by a conviction to help people fight cancer and live life to the fullest. Based in the San Francisco Bay Area, Vivace Therapeutics is anoncology-focused portfolio-based drug discovery and development company adopting a capital-efficient and modality-indifferent approach to bring novel therapies to patients in need. Their experienced management team and world-class scientists work to advance promising drugs and therapeutic technologies that they believe can help conquer cancer. | $25M / Series B / Jun 28, 2017 | ||
| TruTag Technologies, Inc. is a leading authentication and technology solution provider serving businesses and governments around the world. TruTag has the most advanced precision-fabricated, cGMP nano-porous silica manufacturing operation in the world for product authentication across a broad range of industries including pharmaceuticals, food,consumer products, and industrial & electronic parts. TruTag’s authentication platform is complemented by its’ advanced hyperspectral imaging technology, which is focused on providing powerful next-generation inline quality assurance solutions and diagnostics.TruTag Technologies has been recognized by the SPIE Prism Awards, the Edison Awards, Fast Company, R&D 100, and was selected a Technology Pioneer by the World Economic Forum as one of the most influential technology companies in the world. | $21.3M / Series B / Mar 01, 2015 | ||
| TruTag Technologies, Inc. is a leading authentication and technology solution provider serving businesses and governments around the world. TruTag has the most advanced precision-fabricated, cGMP nano-porous silica manufacturing operation in the world for product authentication across a broad range of industries including pharmaceuticals, food,consumer products, and industrial & electronic parts. TruTag’s authentication platform is complemented by its’ advanced hyperspectral imaging technology, which is focused on providing powerful next-generation inline quality assurance solutions and diagnostics.TruTag Technologies has been recognized by the SPIE Prism Awards, the Edison Awards, Fast Company, R&D 100, and was selected a Technology Pioneer by the World Economic Forum as one of the most influential technology companies in the world. | $16.8M / Series A / Jun 16, 2014 |
Co-Investors
About WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve theproductivity of advancing healthcare products through cost-effective and efficient solutions,With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 3,900 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that "every drug can be made and every disease can be treated".
WuXi AppTec Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Edward Hu
Co-CEO
|
|||
Ellis Chu
Chief Financial Officer
|
|||
Ge Li
Founder, Chairman and CEO
|
|||
|
Juan Lagos
Associate Director Upstream Process Development
|
|||
Lina Huang
Senior Director Accounting
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Edward Hu invest in?
Edward Hu invests primarily in Biotechnology, Therapeutics and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Edward Hu?
Public channels for Edward Hu include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Edward Hu last invest?
The most recent investment recorded for Edward Hu closed in Feb 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
